Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Monday, November 18th, TipRanks reports. They currently have a $72.50 target price on the stock. Chardan Capital’s target price indicates a potential upside of 10.92% from the stock’s current price.
Several other equities research analysts have also weighed in on CRSP. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 target price on shares of Crispr Therapeutics in a report on Wednesday, July 31st. BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 15th. William Blair reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Tuesday, July 30th. Canaccord Genuity initiated coverage on shares of Crispr Therapeutics in a report on Friday, July 26th. They issued a “buy” rating and a $72.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus price target of $69.54.
NASDAQ CRSP traded down $0.67 during trading hours on Monday, hitting $65.36. The company’s stock had a trading volume of 737,055 shares, compared to its average volume of 1,650,207. The stock has a fifty day moving average of $58.93 and a 200 day moving average of $48.44. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.
In related news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Benjamin Edwards Inc. grew its position in shares of Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc boosted its holdings in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after buying an additional 549 shares during the period. US Bancorp DE boosted its holdings in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the period. Coastal Investment Advisors Inc. bought a new stake in shares of Crispr Therapeutics during the 3rd quarter worth about $26,000. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics during the 2nd quarter worth about $39,000. 49.82% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.